Skip to main content

Advertisement

Table 6 Cytogenetics and laboratory follow-up in 3 patients with discrepant findings

From: Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CT

  At baseline At PET/CT imaging At FU BM After consolidation
1 month 4 months 10 months 16 months
Pt 6 Cytogenetics 46, XX, t(8;21)(q22;q22)[19]/46,XX[1]
  WBC (× 109/L) 17.34 0.68 3.41 4.47 17.16 a a
  Hb (g/dL) 7 9.6 10.8 11 13.2 a a
  Platelet (× 109/L) 10 21 13 70 30 a a
  LDH (U/L) 571 169 343 246 1041 a a
Pt 7 Cytogenetics 43-45, XY, del(3)(p11.2), del(5)(q13q33),−7,+8,del(12)(p11.2p11.2), −21[cp20]
  WBC (× 109/L) 19.02 0.85 3.09 3.3 8.2 a a
  Hb (g/dL) 4.6 9.1 7.7 9 9.4 a a
  Platelet (× 109/L) 10 32 176 170 38 a a
  LDH (U/L) 606 347 229 178 418 a a
Pt 9 Cytogenetics 45,X,−Y, t(8;21)(q22;q22), add(14)(q32)[20] : RUNX1-RUNX1T1
  WBC (× 109/L) 30.72 0.66 5.38 11.41 4.65 4.65 6.13
  Hb (g/dL) 3 10.3 12.5 10.5 13.7 15.4 15.2
  Platelet (× 109/L) 11 55 297 49 97 97 105
  LDH (U/L) 706 310 227 306 151 153 178
  1. Pt patient
  2. aPatient 6 and 7 relapsed or were strongly suspected of relapse at 4 months after consolidation